The FDA seized Reactin Plus stock worth ₹11.19 lakh and ordered the firm to recall the drug from the market. | India News

FDA cancels Cipla Pharma's drug sale licenses due to serious storage and handling irregularities at its Pune unit.

Maharashtra FDA cancelled Cipla's Pune unit drug sale licences. Serious irregularities in storage and recall procedures were cited by the regulator. The company failed to fully…